Probable Leptospirosis in the Adventure Traveler with Freshwater Exposure: Narrative Review and Case Series
Abstract
Leptospirosis is an emerging zoonotic infectious disease in the adventure traveler with recreational freshwater exposure. We describe three cases of probable leptospirosis acquired during whitewater rafting trips in rural Ecuador. Rafting took place following periods of heavy rainfall and flooding of rivers, which are well documented risk factors for leptospirosis. Two of our patients presented to our rapid assessment clinic with acute febrile illness after travel to a region with a confirmed leptospirosis outbreak, while the third patient presented four weeks after a convalescent episode of acute febrile jaundice during a dramatic rise in reported leptospirosis cases in Ecuador. Delayed turnaround times for confirmatory microbiologic diagnostics in leptospirosis challenge its management and necessitate provisional clinical diagnosis and empiric antimicrobials based on compatible clinical symptoms, biochemical abnormalities, exposure history, and known outbreak epidemiology. We herein situate the presentations of our patients within the broader literature by reviewing the clinical, diagnostic, therapeutic, and prognostic considerations when caring for leptospirosis patients. Leptospirosis should be considered in the differential diagnosis of all patients presenting with acute febrile illness following adventure travel with freshwater exposure, and empiric treatment should be considered given the absence of readily available confirmatory microbiologic testing.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.